Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merger Outlook For 2004: Pfizer Fortunes Key To More M&A, Analysts Say

Executive Summary

A demonstration by Pfizer of renewed vigor following the acquisition of Pharmacia could kick off another round of merger & acquisition activity in 2004, securities analysts predict

You may also be interested in...



Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents

Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent

GSK Near-Term Pipeline Relies On Line Extensions; “Wall” Of NMEs To Come

GlaxoSmithKline is relying primarily on line extensions and supplemental indications to fill its nearer-term pipeline before the effect of a revamped R&D effort kicks in

Merck Drops Strict “No Merger” Policy, But Still Prefers Licensing Deals

Merck appears to be distancing itself from a blanket "no merger" policy by offering a formula under which it would consider a large-scale transaction

Related Content

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel